

# New Renal Function Assay

# AXINON<sup>®</sup> GFR(NMR) Assay

For Research Use Only

The new AXINON<sup>®</sup> GFR(NMR) assay helps improve the accuracy of research associated with glomerular filtration rate (GFR). The new assay combines two novel biomarkers, valine and myo-inositol, with creatinine and cystatin C using highly accurate nuclear magnetic resonance (NMR) spectroscopy.

## AXINON<sup>®</sup> GFR(NMR) Assay\*

- **Improves Accuracy**
  - More closely correlates with measured GFR (mGFR) compared to traditional GFR equations
- **Overcomes Bias**
  - Accounts for non-renal factors, i.e., comorbidities, age, race, BMI and muscle mass
- **Provides a Clearer Picture of GFR Status**
  - Increases accuracy and confidence in kidney function research
- **Uses Exploratory Biomarker Mining**
  - Enhances personalized medicine research

\* AXINON<sup>®</sup> GFR(NMR) is available as a CE-labeled in vitro diagnostic product in the European Union and as a Research-Use-Only product in the United States.



numares  
HEALTH

# AXINON® GFR(NMR) Technology


Nuclear magnetic resonance (NMR) spectroscopy is a proven and highly accurate test technology that assesses a variety of compounds at a molecular level. For GFR(NMR), the generated signals from serum samples correspond with concentrations of the targeted metabolites, with results reported in mL/minute/1.73 m<sup>2</sup>.

## AXINON® GFR(NMR)

### Biomarker Constellation

The AXINON® GFR(NMR) “biomarker constellation” combines new NMR-measured metabolite biomarkers, valine and myo-inositol, with creatinine, cystatin C and demographic information.

A single result from this constellation generates a more accurate GFR result compared to standard eGFR equations.



For more information, contact  
**Dan Lindsay** at **+1 818.606.4125** or  
**Dan.Lindsay@numares.com**

For investigator-initiated studies or other research  
collaborations, contact **David DeBonville** at  
**David.DeBonville@numares.com**

[www.numares.com](http://www.numares.com)

#### SELECTED PUBLICATIONS

Meeusen J, Stämmler F, Dasari S, et al. (2022). *Front. Med.* 9:988989.  
Fuhmann M, Santamaria A, Scott, R, et al. (2022). *Diagnostics* 2022, 12(5), 1120.  
Stämmler F, Grassi M, Meeusen JW, et al. (2021). *Diagnostics (Basel)*. 2021 Dec 7;11(12):2291.  
Ehrich J, Dubourg L, Hansson S, et al. (2021). *Diagnostics (Basel)*. 2021 Feb 3;11(2):234.

**Numares Health**  
1900 West Loop South, Ste 1550  
Houston, TX 77027 USA



©2024 Numares Health. AXINON® is a registered trademark of Numares Health. All rights reserved. NPM 164-02